Epcoritamab Induces Potent Anti-Tumor Activity against Malignant B-Cells from Patients with DLBCL, FL and MCL, Irrespective of Prior CD20 Monoclonal Antibody Treatment

Researchers assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed and relapsed/refractory B-cell non-Hodgkin lymphoma patients.
[Blood Cancer Journal]
van der Horst, H. J., de Jonge, A. V., Hiemstra, I. H., Gelderloos, A. T., Berry, D. R. A. I., Hijmering, N. J., van Essen, H. F., de Jong, D., Chamuleau, M. E. D., Zweegman, S., Breij, E. C. W., Roemer, M. G. M., & Mutis, T. (2021). Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer Journal, 11(2), 1–8. https://doi.org/10.1038/s41408-021-00430-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Deferasirox Induces Cyclin D1 Degradation and Apoptosis in Mantle Cell Lymphoma in a Reactive Oxygen Species- and GSK3β-Dependent Mechanism

Scientists demonstrated that the clinically approved iron chelator deferasirox exerts an anti‐tumoral effect in mantle cell lymphoma cell lines and patient cells.
[British Journal of Haematology]
Samara, A., Shapira, S., Lubin, I., Shpilberg, O., Avigad, S., Granot, G., & Raanani, P. (n.d.). Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism. British Journal of Haematology, n/a(n/a). https://doi.org/https://doi.org/10.1111/bjh.17284 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Dynamics of Genome Architecture and Chromatin Function during Human B Cell Differentiation and Neoplastic Transformation

Scientists integrated in situ Hi-C and nine additional omics layers. Beyond conventional active and inactive compartments, they uncovered a highly-dynamic intermediate compartment enriched in poised and polycomb-repressed chromatin.
[Nature Communications]
Vilarrasa-Blasi, R., Soler-Vila, P., Verdaguer-Dot, N., Russiñol, N., Di Stefano, M., Chapaprieta, V., Clot, G., Farabella, I., Cuscó, P., Kulis, M., Agirre, X., Prosper, F., Beekman, R., Beà, S., Colomer, D., Stunnenberg, H. G., Gut, I., Campo, E., Marti-Renom, M. A., & Martin-Subero, J. I. (2021). Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. Nature Communications, 12(1), 651. https://doi.org/10.1038/s41467-020-20849-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

Targeting eIF4F Translation Initiation Complex with SBI-756 Sensitises B Lymphoma Cells to Venetoclax

Investigators tested inhibitors of cap-dependent mRNA translation for the ability to sensitise diffuse large B-cell lymphoma and mantle cell lymphoma cells to apoptosis by venetoclax.
[British Journal of Cancer]
Herzog, L., Walters, B., Buono, R., Lee, J. S., Mallya, S., Fung, A., Chiu, H., Nguyen, N., Li, B., Pinkerton, A. B., Jackson, M. R., Schneider, R. J., Ronai, Z. A., & Fruman, D. A. (2020). Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. British Journal of Cancer, 1–12. https://doi.org/10.1038/s41416-020-01205-9 Cite
Abstract
Bookmark

No account yet? Register

0
Share

US FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Kite announced that the FDA has granted accelerated approval to Tecartus™, the first and only approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
[Gilead Sciences, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share
Share